The immune response of nano carbon-based photic-driving vaccines to severe acute respiratory syndrome coronavirus 2

Abstract

As the most severe novel infectious disease in this century, coronavirus disease 2019 (COVID-19) faces tremendous challenges due to the hysteresis of drugs and vaccine development. Elucidating the panoramic mechanism of coronavirus-host immune interaction is a strategy for disease surveillance, diagnosis, treatment, prevention, and immunity assessment of COVID-19. A robust carbon nanotube (CNT)-based photic vaccine technology contributes to address the core scientific issues of these challenges. This perspective states the latest prevention and control strategy of CNT-based photic vaccine and its broad-spectrum resistance to high transmissible and pathogenic variants. Furthermore, this perspective covers the potential immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under the CNT-based photic vaccine intervention and finally evaluates its efficacy and the underlying interactive mechanisms. In the future, findings of the highly efficient and conservative T cell epitopes depending on an intelligent chem-physical modulation would provide a promising basis for the development of next generation vaccines. Ideally, these next generation vaccines are prone to be with the function of dynamic allostery responding to the chem-physical changing and present the allosteric epitopes which are affinity to the viral variation.

Keywords

Severe acute respiratory syndrome coronavirus 2 / carbon nanotube / photic-driving / vaccines / immune response / allostery / epitope

References

[1] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19: 141-54. Erratum in: Nat Rev Microbiol. 2022;20:315.

[2] Kraemer MUG, Yang CH, Gutierrez B, Wu CH, Klein B, Pigott DM; Open COVID-19 Data Working Group; du Plessis L, Faria NR, Li R, Hanage WP, Brownstein JS, Layan M, et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science. 2020; 368: 493-7.

[3] Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012; 165: 112-7. Erratum in: Virus Res. 2023;323:198952.

[4] Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, et al. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell. 2021; 184: 460-75.e21.

[5] Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020; 11: 3810.

[6] Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020; 16: 1708-17.

[7] Dunham AM, Rieder TN, Humbyrd CJ. A bioethical perspective for navigating moral dilemmas amidst the COVID-19 pandemic. J Am Acad Orthop Surg. 2020; 28: 471-6.

[8] Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020; 7: ofaa102.

[9] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 324: 782-93.

[10] WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021; 384: 497-511.

[11] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181: 271-80.e8.

[12] Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, et al. Carbon-based nanomaterials: promising antiviral agents to combat COVID-19 in the microbial-resistant era. ACS Nano. 2021; 15: 8069-86.

[13] Buonanno M, Welch D, Shuryak I, Brenner DJ. Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses. Sci Rep. 2020; 10: 10285. Erratum in: Sci Rep. 2021;11:19569.

[14] Chen Y, Jafari I, Zhong Y, Chee MJ, Hu J. Degradation of organics and formation of DBPs in the combined LED-UV and chlorine processes: effects of water matrix and fluorescence analysis. Sci Total Environ. 2022; 846: 157454.

[15] Campana R, Moroni S, Paolucci D, Federici M, Casettari L, Frangipani E. Efficacy of UV and UV-LEDs irradiation models for microbial inactivation applicable to automated sterile drug compounding. J Pharm Sci. 2023; 112: 2389-92.

[16] Balasubramanian D. Ultraviolet radiation and cataract. J Ocul Pharmacol Ther. 2000; 16: 285-97.

[17] Welch D, Buonanno M, Grilj V, Shuryak I, Crickmore C, Bigelow AW, et al. Far-UVC light: a new tool to control the spread of airborne-mediated microbial diseases. Sci Rep. 2018; 8: 2752. Erratum in: Sci Rep. 2021;11:18122.

[18] Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69: 635-64.

[19] de Carvalho Lima EN, Octaviano ALM, Piqueira JRC, Diaz RS, Justo JF. Coronavirus and carbon nanotubes: seeking immunological relationships to discover immunotherapeutic possibilities. Int J Nanomedicine. 2022; 17: 751-81.

[20] Rai M, Bonde S, Yadav A, Bhowmik A, Rathod S, Ingle P, et al. Nanotechnology as a shield against COVID-19: current advancement and limitations. Viruses. 2021; 13: 1224.

[21] Thakur N, Thakur S, Chatterjee S, Das J, Sil PC. Nanoparticles as smart carriers for enhanced cancer immunotherapy. Front Chem. 2020; 8: 597806.

[22] Mehra NK, Palakurthi S. Interactions between carbon nanotubes and bioactives: a drug delivery perspective. Drug Discov Today. 2016; 21: 585-97.

[23] Zare H, Ahmadi S, Ghasemi A, Ghanbari M, Rabiee N, Bagherzadeh M, et al. Carbon nanotubes: smart drug/gene delivery carriers. Int J Nanomedicine. 2021; 16: 1681-706. Erratum in: Int J Nanomedicine. 2021; 16:7283-4.

[24] Rahamathulla M, Bhosale RR, Osmani RAM, Mahima KC, Johnson AP, Hani U, et al. Carbon nanotubes: current perspectives on diverse applications in targeted drug delivery and therapies. Materials (Basel). 2021; 14: 6707.

[25] Kofoed Andersen C, Khatri S, Hansen J, Slott S, Pavan Parvathaneni R, Mendes AC, et al. Carbon nanotubes-potent carriers for targeted drug delivery in rheumatoid arthritis. Pharmaceutics. 2021; 13: 453.

[26] Son KH, Hong JH, Lee JW. Carbon nanotubes as cancer therapeutic carriers and mediators. Int J Nanomedicine. 2016; 11: 5163-85.

[27] Besteman K, Lee JO, Wiertz FGM, Heering HA, Dekker C. Enzyme-coated carbon nanotubes as single-molecule biosensors. Nano Lett. 2003; 3: 727-30.

[28] Maestro LM, Haro-González P, del Rosal B, Ramiro J, Caamaño AJ, Carrasco E, et al. Heating efficiency of multi-walled carbon nanotubes in the first and second biological windows. Nanoscale. 2013; 5: 7882-9.

[29] Burke A, Ding X, Singh R, Kraft RA, Levi-Polyachenko N, Rylander MN, et al. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A. 2009; 106: 12897-902.

[30] Yang J. Real nano “light vaccine” will benefit to COVID-19 pandemic control. Nanomicro Lett. 2021; 13: 185.

[31] Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581: 215-20.

[32] Yang J. Inhibition of SARS-CoV-2 replication by acidizing and RNA lyase-modified carbon nanotubes combined with photodynamic thermal effect. J Explor Res Pharmacol. 2020; 5: 18-23.

[33] Yang J, Zhang X, Lv Z, Lu L. Right nano cargoes is vital for CAR T cell therapy to myocardial fibrosis. Science. 2022; 375: abo5628.

[34] Pondman KM, Salvador-Morales C, Paudyal B, Sim RB, Kishore U. Interactions of the innate immune system with carbon nanotubes. Nanoscale Horiz. 2017; 2: 174-86.

[35] Hamad I, Christy Hunter A, Rutt KJ, Liu Z, Dai H, Moein Moghimi S. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol. 2008; 45: 3797-803.

[36] Xie Y, Li H, Luo X, Li H, Gao Q, Zhang L, et al. IBS 2.0: an upgraded illustrator for the visualization of biological sequences. Nucleic Acids Res. 2022; 50: W420-6.